tetano
Editor, Senior Moderator
Vaccine
Available online 14 March 2013
In Press, Uncorrected Proof ? Note to users
Cover image
Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients
Alberto Cagigia, 1, Corresponding author contact information, E-mail the corresponding author, E-mail the corresponding author,
Simone Pensierosob, 1,
Nicolas Ruffinb,
Stefano Sammichelib,
Rigmor Thorstenssonc,
Qiang Pan-Hammarstr?ma,
Bo Hejdemand,
Anna Nilssonb, e,
Francesca Chiodib
a Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
b Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
c The Swedish Institute for Communicable Disease Control, Stockholm, Sweden
d Department of Infectious Diseases, Stockholm South General Hospital, Stockholm, Sweden
e Pediatric Infectious Diseases Unit, Department of Women and Child Health, Karolinska Institutet, Stockholm, Sweden
http://dx.doi.org/10.1016/j.vaccine.2013.03.002
Highlights
?
Percentage of responders was greater in HC and ART+ compared to Na?ve.
?
In vitro AID increase correlated to in vivo A(H1N1)pdm09 antibody increase.
?
Higher AID expression correlated to immune-protection to A(H1N1)pdm09.
Abstract
The relevance of CD4+T-cells, viral load and age in the immunological response to influenza infection and vaccination in HIV-1 infected individuals has previously been pointed out. Our study aimed at assessing, in the setting of 2009 A(H1N1)pdm09 influenza vaccination, whether quantification of activation-induced deaminase (AID) expression in blood B-cells may provide additional indications for predicting antibody response to vaccination in HIV-1 infected patients with similar CD4+T-cell counts and age. Forty-seven healthy controls, 37 ART-treated and 17 treatment-na?ve HIV-1 infected patients were enrolled in the study. Blood was collected prior to A(H1N1)pdm09 vaccination and at 1, 3 and 6 months after vaccination. Antibody titers to A(H1N1)pdm09 vaccine were measured by hemagglutination inhibition (HI) assay while the mRNA expression levels of AID were measured by quantitative real time PCR. Upon B-cell activation in vitro, AID increase correlated to antibody response to the A(H1N1)pdm09 vaccine at 1 month after vaccination in all individuals. In addition, the maximum expression levels of AID were significantly higher in those individuals who still carried protective levels of A(H1N1)pdm09 antibodies after 6 months from vaccination. No correlation was found between CD4+T-cell counts or age at vaccination or HIV-1 viral load and levels of A(H1N1)pdm09 antibodies. Assessing AID expression before vaccination may be an additional useful tool for defining a vaccination strategy in immune-compromised individuals at risk of immunization failure.
http://www.sciencedirect.com/science/article/pii/S0264410X13002612
Available online 14 March 2013
In Press, Uncorrected Proof ? Note to users
Cover image
Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients
Alberto Cagigia, 1, Corresponding author contact information, E-mail the corresponding author, E-mail the corresponding author,
Simone Pensierosob, 1,
Nicolas Ruffinb,
Stefano Sammichelib,
Rigmor Thorstenssonc,
Qiang Pan-Hammarstr?ma,
Bo Hejdemand,
Anna Nilssonb, e,
Francesca Chiodib
a Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
b Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
c The Swedish Institute for Communicable Disease Control, Stockholm, Sweden
d Department of Infectious Diseases, Stockholm South General Hospital, Stockholm, Sweden
e Pediatric Infectious Diseases Unit, Department of Women and Child Health, Karolinska Institutet, Stockholm, Sweden
http://dx.doi.org/10.1016/j.vaccine.2013.03.002
Highlights
?
Percentage of responders was greater in HC and ART+ compared to Na?ve.
?
In vitro AID increase correlated to in vivo A(H1N1)pdm09 antibody increase.
?
Higher AID expression correlated to immune-protection to A(H1N1)pdm09.
Abstract
The relevance of CD4+T-cells, viral load and age in the immunological response to influenza infection and vaccination in HIV-1 infected individuals has previously been pointed out. Our study aimed at assessing, in the setting of 2009 A(H1N1)pdm09 influenza vaccination, whether quantification of activation-induced deaminase (AID) expression in blood B-cells may provide additional indications for predicting antibody response to vaccination in HIV-1 infected patients with similar CD4+T-cell counts and age. Forty-seven healthy controls, 37 ART-treated and 17 treatment-na?ve HIV-1 infected patients were enrolled in the study. Blood was collected prior to A(H1N1)pdm09 vaccination and at 1, 3 and 6 months after vaccination. Antibody titers to A(H1N1)pdm09 vaccine were measured by hemagglutination inhibition (HI) assay while the mRNA expression levels of AID were measured by quantitative real time PCR. Upon B-cell activation in vitro, AID increase correlated to antibody response to the A(H1N1)pdm09 vaccine at 1 month after vaccination in all individuals. In addition, the maximum expression levels of AID were significantly higher in those individuals who still carried protective levels of A(H1N1)pdm09 antibodies after 6 months from vaccination. No correlation was found between CD4+T-cell counts or age at vaccination or HIV-1 viral load and levels of A(H1N1)pdm09 antibodies. Assessing AID expression before vaccination may be an additional useful tool for defining a vaccination strategy in immune-compromised individuals at risk of immunization failure.
http://www.sciencedirect.com/science/article/pii/S0264410X13002612